These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29979855)

  • 41. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders.
    Gupta S
    Vasc Health Risk Manag; 2016; 12():421-433. PubMed ID: 27877050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Significance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia.
    Neumann CL; Schettler E; Schettler VJ
    Blood Purif; 2016; 41(4):270-6. PubMed ID: 26789774
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Improvement in cardiovascular prognosis of type 2 diabetes mellitus, is it a reality?].
    Ruiz-Hurtado G; Vigil L; Ruilope LM
    Hipertens Riesgo Vasc; 2016; 33(4):123-125. PubMed ID: 27770841
    [No Abstract]   [Full Text] [Related]  

  • 46. Tying Reimbursement to Outcomes Is an Ideal Strategy for PCSK9 Inhibitors.
    Blumenthal DM; Goldman D; Jena AB
    JAMA Cardiol; 2017 Oct; 2(10):1063-1064. PubMed ID: 28854318
    [No Abstract]   [Full Text] [Related]  

  • 47. PCSK9 Inhibitors: A Technology Worth Paying For?
    Weintraub WS; Gidding SS
    Pharmacoeconomics; 2016 Mar; 34(3):217-20. PubMed ID: 26689785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions.
    Rallidis LS; Lekakis J
    Hellenic J Cardiol; 2016; 57(2):86-91. PubMed ID: 27445021
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PCSK9 Inhibitors: An Innovative Approach to Treating Hyperlipidemia.
    Sible AM; Nawarskas JJ; Anderson JR
    Cardiol Rev; 2016; 24(3):141-52. PubMed ID: 26886466
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
    Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
    Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Additional insights on how best to utilize statins.
    Feeman WE
    J Fam Pract; 2014 Mar; 63(3):128. PubMed ID: 24701605
    [No Abstract]   [Full Text] [Related]  

  • 52. Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.
    Li C; Lin L; Zhang W; Zhou L; Wang H; Luo X; Luo H; Cai Y; Zeng C
    J Am Heart Assoc; 2015 Jun; 4(6):e001937. PubMed ID: 26077586
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Lipid-lowering therapy in Europe and the United States - treat to target or fire and forget?].
    Pfetsch V; Sanin V; Koenig W
    Dtsch Med Wochenschr; 2016 Jun; 141(12):857-62. PubMed ID: 27305301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of high blood cholesterol in patients with coronary heart disease].
    Nagai Y; Yanagi K; Yamashita S; Takemura K; Matsuzawa Y
    Nihon Rinsho; 1994 Jul; 52 Suppl(Pt 1):1088-94. PubMed ID: 12436661
    [No Abstract]   [Full Text] [Related]  

  • 55. Niacin: old habits die hard.
    Haynes R; Rahimi K
    Heart; 2016 Feb; 102(3):170-1. PubMed ID: 26769376
    [No Abstract]   [Full Text] [Related]  

  • 56. Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims.
    Tenenbaum A; Fisman EZ; Motro M
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1978; author reply 1978-9. PubMed ID: 15070976
    [No Abstract]   [Full Text] [Related]  

  • 57. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.
    Okere AN; Serra C
    Pharmacotherapy; 2015 Aug; 35(8):771-9. PubMed ID: 26256279
    [TBL] [Abstract][Full Text] [Related]  

  • 59. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management?
    Stein EA
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):97-105. PubMed ID: 26859553
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PCSK9 Inhibitors: Economics and Policy.
    Hlatky MA; Kazi DS
    J Am Coll Cardiol; 2017 Nov; 70(21):2677-2687. PubMed ID: 29169476
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.